The Bulgarian Competition Authority rules on parallel trade of pharmaceutical products and their limitations (Sopharma)

Restrictions of Parallel Trade in Pharmaceuticals – Carte Blanche from the Bulgarian Competition Authority?* The Bulgarian Competition Protection Commission (“CPC” or “Commission”) has recently issued an important decision regarding the parallel trade of pharmaceuticals and the possibilities for its limitations. In September 2013 ,- Sopharma Trading JSC (“Sopharma”), which is the affiliated distributor of one of the leading Bulgarian pharmaceutical companies, filed with the CPC a complaint against several other companies with respect to practices, alleged to be measures to control or limit parallel trade. The CPC initiated a procedure, against two companies – Abbott Products Ltd. (“Abbott”) and Sting Ltd. (“Sting”). In December 2014, the CPC rendered its decision, which gave rise to extensive

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Eleonora Mateina, The Bulgarian Competition Authority rules on parallel trade of pharmaceutical products and their limitations (Sopharma), 17 December 2014, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 76322

Visites 489

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues